Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Aug 6, 2026Quarterly report · 10-QFiled by the company itself.Open the filing ↗
- Aug 6, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
- May 7, 2026Quarterly report · 10-QFiled by the company itself.Open the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record1,2589 flagged findings
Reported transactions (Form 4)80since Feb 17, 2026 · and 25 other holdings
Corporate events (8-K)30since Jun 2, 2023
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
What the company does
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
Source: Wikipedia (CC BY-SA 4.0) · copied on Sep 3, 2026 · may not reflect recent changes.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-05-07listing compliance noticerecentOpen filing ↗“…volatile. • Future issuances or sales of our common stock, or the perception that such issuances or sales may occur, may depress our…”
- 2026-03-05share offering or dilution eventrecentOpen filing ↗“…at an exercise price of $ 1.95 per share and 183,824 shares of Lexicon’s common stock at an exercise price of $ 2.38 per share,…”
- 2026-03-05listing compliance noticerecentOpen filing ↗“…stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these…”
+1 more passage from the same document
- “…meet Nasdaq continued listing requirements in the future, including minimum trading price, Nasdaq may take action to delist our…”
- 2026-03-05export control restrictionsrecentOpen filing ↗“…in a cost effective manner. We rely on third party drug product contract manufacturers in Canada and China who then…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
The 25 most recent filings (of 1,258)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Aug 6, 26S-3 ↗Securities offering
- Aug 6, 2610-Q ↗Quarterly report
- Aug 6, 268-K ↗Current report · Results
- Aug 6, 26SCHEDULE 13G/A ↗Passive stake · FMR LLC · 11.7% · event on Jun 30, 26 · amendment
Insider transaction · 8 Form 4 filingsshow all 8hide
- May 8, 26SCHEDULE 13D/A ↗Stake with intent to influence · Artal Participations S.a r.l. · 39.4% · event on Apr 30, 26 · amendment
- May 7, 2610-Q ↗Quarterly report
- May 7, 268-K ↗Current report · Results
- May 6, 268-K ↗Current report · Sold unregistered shares
Insider transaction · 7 Form 4 filingsshow all 7hide
- Apr 30, 268-K ↗Current report · Entered a material agreement
- Mar 16, 26DEFA14A ↗Shareholder meeting and votes
1,258 filings on record, the oldest from May 5, 00.
Listing the 25 most recent filings of the 1,258 on record.
511735
- May 6, 26Sold unregistered shares+4 more in the same filing8-K 3.02 ↗
- Apr 30, 26Entered a material agreement+4 more in the same filing8-K 1.01 ↗
- Feb 2, 26Sold unregistered shares+5 more in the same filing8-K 3.02 ↗
- Jun 3, 25Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Mar 28, 25Entered a material agreement+1 more in the same filing8-K 1.01 ↗
- Jan 7, 25Listing notice (8-K 3.01)8-K 3.01 ↗
- Jan 2, 25A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Nov 22, 24Restructuring plan with committed costs8-K 2.05 ↗
- Nov 20, 24A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Oct 16, 24Entered a material agreement8-K 1.01 ↗
- Sep 16, 24A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Jul 8, 24A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
11 older filings not shown · The record reaches back to Nov 5, 04.
Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.
- Aug 4, 20Restructuring plan with committed costs+1 more in the same filing8-K 2.05 ↗
- Mar 4, 15Listing notice (8-K 3.01)8-K 3.01 ↗
- Jan 13, 14Restructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗
The full record holds 5 stress filings.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13D: stake and stated purpose
Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.
- Artal Participations S.a r.l.39.4%Apr 30, 26SCHEDULE 13D/A ↗18 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- FMR LLC11.7%Jun 30, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Stock compensation, tax and giftsshow the 34 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Jun 3, 26Compensationamount n/aRAYMOND DEBBANE↗
- Jun 3, 26Compensationamount n/aPhilippe Amouyal↗
- Jun 3, 26Compensationamount n/aSAM L BARKER↗
- Jun 3, 26Compensationamount n/aIvan Cheung↗
- Jun 3, 26Compensationamount n/aCHRISTOPHER J SOBECKI↗
- Jun 3, 26Compensationamount n/aDiane E. Sullivan↗
- Jun 3, 26Compensationamount n/aJudith L Swain↗
- Apr 30, 26Compensationamount n/aArtal Participations S.a r.l.↗
- Feb 28, 26Compensationamount n/aMichael ExtonChief Executive Officer↗
- Feb 28, 26Tax$301KMichael ExtonChief Executive Officer↗
- Feb 28, 26Compensationamount n/aScott M CoianteSVP, Chief Financial Officer↗
- Feb 28, 26Tax$81KScott M CoianteSVP, Chief Financial Officer↗
- Feb 28, 26Compensationamount n/aBrian T CrumSVP, General Counsel & Secr.↗
- Feb 28, 26Compensationamount n/aBrian T CrumSVP, General Counsel & Secr.↗
- Feb 28, 26Compensationamount n/aBrian T CrumSVP, General Counsel & Secr.↗
- Feb 28, 26Tax$154KBrian T CrumSVP, General Counsel & Secr.↗
- Feb 28, 26Compensationamount n/aLisa DeFrancescoSVP, IR and Corp Comm↗
- Feb 28, 26Compensationamount n/aLisa DeFrancescoSVP, IR and Corp Comm↗
- Feb 28, 26Tax$110KLisa DeFrancescoSVP, IR and Corp Comm↗
- Feb 28, 26Compensationamount n/aSuma GopinathanSVP, Discovery↗
- Feb 28, 26Compensationamount n/aSuma GopinathanSVP, Discovery↗
- Feb 28, 26Compensationamount n/aSuma GopinathanSVP, Discovery↗
- Feb 28, 26Tax$36KSuma GopinathanSVP, Discovery↗
- Feb 28, 26Compensationamount n/aCraig B GranowitzSVP, Chief Medical Officer↗
- Feb 28, 26Compensationamount n/aCraig B GranowitzSVP, Chief Medical Officer↗
- Feb 28, 26Compensationamount n/aCraig B GranowitzSVP, Chief Medical Officer↗
- Feb 28, 26Tax$160KCraig B GranowitzSVP, Chief Medical Officer↗
- Feb 28, 26Compensationamount n/aRachel Yap MartensSVP, Partnerships & Corp Strat↗
- Feb 28, 26Tax$53KRachel Yap MartensSVP, Partnerships & Corp Strat↗
- Feb 28, 26Compensationamount n/aWendy McDermottSVP, Human Resources↗
- Feb 28, 26Compensationamount n/aWendy McDermottSVP, Human Resources↗
- Feb 28, 26Compensationamount n/aWendy McDermottSVP, Human Resources↗
- Feb 28, 26Tax$100KWendy McDermottSVP, Human Resources↗
- Feb 17, 26Compensation$2.7MArtal Participations S.a r.l.↗
The full record holds 167 transactions and goes back to Feb 9, 23.
Its sector and its market
Lexicon Pharmaceuticals, Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Lexicon Pharmaceuticals, Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Lexicon Pharmaceuticals, Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 1,258 documents on file, from May 5, 2000 to Aug 6, 2026.
- Company description
- Wikipedia, read on Sep 3, 2026.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.